COL4A3 (Collagen alpha-3(IV) chain) variants and mutations
COL4A3 (also known as Collagen alpha-3(IV) chain) is a human protein-coding gene encoding a collagen alpha-3(IV) chain protein. It contributes to the alpha3-alpha4-alpha5 type IV collagen network that forms the specialized basement membrane of the renal glomerulus, cochlea, and eye. Pathogenic variants cause Alport-spectrum disease and thin-basement-membrane nephropathy, with variable kidney and hearing involvement. This analysis covers 2,407 COL4A3 variants and mutations. Of these, 76% have computational variant effect predictions. Disease context includes autosomal dominant Alport syndrome, Alport syndrome 3b, autosomal recessive, and Alport syndrome. Example COL4A3 variants include M1L, M1T, and M1V.
Variant analysis overview
- Gene: COL4A3
- Protein: Collagen alpha-3(IV) chain
- UniProt accession: Q01955
- Organism: Homo sapiens
- Variants analyzed: 2407
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 2,213 unspecified-consequence records; 114 missense variants; 51 synonymous variants; 14 frameshift variants; 4 in-frame deletions; 1 in-frame insertions; 6 splice-region variants; 3 stop-gained variants; 1 substitution
- Prediction scores: 1,831 variants have prediction scores (76% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: autosomal dominant Alport syndrome, Alport syndrome 3b, autosomal recessive, Alport syndrome, autosomal recessive Alport syndrome, Hematuria, Benign familial neonatal seizures, Dupuytren Contracture, hematuria, benign familial, 2, hematuria, benign familial, 1, hereditary disease, hematuria, benign familial, albuminuria.
Protein structure and variant hotspots
- Protein features: 1 domains; 1 post-translational modification sites.
- Structural context: 263 variants have structural context.
- PTM context: 1 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable COL4A3 variants
Examples include M1L, M1T, M1V, S2R, S2I, S2S, A3T, A3S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1L (p.Met1Leu), rs1396602090, ClinGen CA350845868, ClinVar RCV000670747, ClinVar RCV001382714, MetaLR 0.47, MetaSVM -0.48, Pathogenic/Likely pathogenic, Alport syndrome; Autosomal recessive Alport syndrome; not provided
- M1T (p.Met1Thr), rs1553725815, ClinGen CA350845870, ClinVar RCV000673067, MetaLR 0.58, MetaSVM 0.02, Likely pathogenic, Autosomal recessive Alport syndrome
- M1V (p.Met1Val), rs1396602090, ClinGen CA350845866, ClinVar RCV002597219, MetaLR 0.47, MetaSVM -0.48, Pathogenic/Likely pathogenic, not provided; Alport syndrome
- S2R (p.Ser2Arg), TOPMed rs1385822999, gnomAD rs1385822999, REVEL 0.18, CADD 10.60, Uncertain significance, not provided
- S2I (p.Ser2Ile), gnomAD 2-227164731-G-T, REVEL 0.10, CADD 9.46
- S2S (p.Ser2Ser), rs1385822999, gnomAD 2-227164732-C-T, CADD 8.82
- A3T (p.Ala3Thr), gnomAD 2-227164733-G-A, REVEL 0.17, CADD 6.26
- A3S (p.Ala3Ser), gnomAD 2-227164733-G-T, REVEL 0.12, CADD 1.76
- A3D (p.Ala3Asp), gnomAD 2-227164734-C-A, REVEL 0.16, CADD 14.90
- R4Q (p.Arg4Gln), rs921905047, ClinGen CA66565365, ClinVar RCV001758293, ClinVar RCV004785297, REVEL 0.16, CADD 12.50, Uncertain significance, Inborn genetic diseases; Autosomal dominant Alport syndrome; Hematuria, benign f
- R4R (p.Arg4Arg), gnomAD 2-227164736-C-A, CADD 3.72
- R4W (p.Arg4Trp), gnomAD 2-227164736-C-T, REVEL 0.17, CADD 13.00
- R4G (p.Arg4Gly), gnomAD 2-227164736-C-G, REVEL 0.13, CADD 2.61
- R4P (p.Arg4Pro), gnomAD 2-227164737-G-C, REVEL 0.20, CADD 14.70
- R4L (p.Arg4Leu), gnomAD 2-227164737-G-T, REVEL 0.14, CADD 13.60
- T5A (p.Thr5Ala), gnomAD 2-227164739-A-G, REVEL 0.17, CADD 1.69
- T5N (p.Thr5Asn), gnomAD 2-227164740-C-A, REVEL 0.20, CADD 0.62
- T5T (p.Thr5Thr), rs1439020670, gnomAD 2-227164741-C-A, CADD 1.26
- A6D (p.Ala6Asp), rs1317800639, ClinGen CA350845938, ClinVar RCV003551427, TOPMed rs1317800639, REVEL 0.53, CADD 10.60, Uncertain significance, not provided
- A6S (p.Ala6Ser), rs770024296, ClinGen CA2145884, ClinVar RCV002266224, ClinVar RCV003227066, REVEL 0.21, CADD 5.51, Uncertain significance, not specified; not provided
- A6V (p.Ala6Val), TOPMed rs1317800639, gnomAD rs1317800639, REVEL 0.14, CADD 9.43, Uncertain significance
- A6T (p.Ala6Thr), gnomAD 2-227164742-G-A, REVEL 0.15, CADD 8.95
- P7S (p.Pro7Ser), ExAC rs776115817, gnomAD rs776115817, REVEL 0.21, CADD 11.00
- P7T (p.Pro7Thr), gnomAD 2-227164745-C-A, REVEL 0.21, CADD 9.75
- P7H (p.Pro7His), gnomAD 2-227164746-C-A, REVEL 0.35, CADD 5.17
- P7P (p.Pro7Pro), rs530353117, gnomAD 2-227164747-C-A, CADD 2.75
- R8G (p.Arg8Gly), TOPMed rs1051432500, gnomAD rs1051432500, REVEL 0.25, CADD 5.35, Likely benign
- R8K (p.Arg8Lys), TOPMed rs944020939, gnomAD rs944020939, REVEL 0.30, CADD 14.10
- R8Q (p.Arg8Gln), gnomAD 2-227164742-G-GC, CADD 20.50
- R8R (p.Arg8Arg), rs1051432500, gnomAD 2-227164748-A-C, CADD 4.48
- R8M (p.Arg8Met), gnomAD 2-227164749-G-T, REVEL 0.31, CADD 19.00
- R8S (p.Arg8Ser), gnomAD 2-227164750-G-T, REVEL 0.32, CADD 7.46
- P9L (p.Pro9Leu), rs773820821, ClinGen CA66565451, ClinVar RCV003227352, ClinVar RCV003491348, REVEL 0.15, CADD 8.11, Uncertain significance, not provided; Autosomal dominant Alport syndrome; Hematuria, benign familial, 2
- P9S (p.Pro9Ser), rs890999119, ClinGen CA66565436, ClinVar RCV001881491, ClinVar RCV004975776, REVEL 0.23, CADD 0.28, Conflicting interpretations, Inborn genetic diseases; not specified; Autosomal dominant Alport syndrome
- P9T (p.Pro9Thr), gnomAD 2-227164751-C-A, REVEL 0.27, CADD 0.17
- P9Q (p.Pro9Gln), gnomAD 2-227164752-C-A, REVEL 0.15, CADD 9.15
- P9P (p.Pro9Pro), rs918717650, gnomAD 2-227164753-G-T, CADD 5.41
- Q10* (p.Gln10Ter), rs1453590085, ClinGen CA350845978, ClinVar RCV000995722, ClinVar RCV001238070, CADD 34.00, Pathogenic
- Q10R (p.Gln10Arg), rs769170197, ClinGen CA2145888, ClinVar RCV003673887, ExAC rs769170197, REVEL 0.12, CADD 4.25, Likely benign, not provided
- Q10K (p.Gln10Lys), gnomAD 2-227164754-C-A, REVEL 0.20, CADD 9.95
- Q10Q (p.Gln10Gln), rs2065145679, gnomAD 2-227164756-G-A, CADD 3.83
- V11M (p.Val11Met), ExAC rs774004775, REVEL 0.20, CADD 12.60
- V11L (p.Val11Leu), gnomAD 2-227164757-G-T, REVEL 0.15, CADD 4.96
- V11E (p.Val11Glu), gnomAD 2-227164758-T-A, REVEL 0.18, CADD 15.50
- V11V (p.Val11Val), rs1262245295, gnomAD 2-227164759-G-T, CADD 2.82
- L12I (p.Leu12Ile), gnomAD 2-227164760-C-A, REVEL 0.13, CADD 6.56
- L12P (p.Leu12Pro), gnomAD 2-227164761-T-C, REVEL 0.41, CADD 16.60
- L12L (p.Leu12Leu), rs1189095338, gnomAD 2-227164762-C-A, CADD 7.72
- L13M (p.Leu13Met), gnomAD 2-227164763-C-A, REVEL 0.20, CADD 13.50
- L13P (p.Leu13Pro), gnomAD 2-227164764-T-C, REVEL 0.30, CADD 16.30
- L13L (p.Leu13Leu), rs1172751081, gnomAD 2-227164765-G-T, CADD 7.79
- p.Leu14 Leu21del, rs876657397, gnomAD 2-227164755-AGGTG, CADD 15.20
- L14L (p.Leu14Leu), gnomAD 2-227164766-C-T, CADD 9.25
- L14M (p.Leu14Met), gnomAD 2-227164766-C-A, REVEL 0.13, CADD 12.80
- L14P (p.Leu14Pro), gnomAD 2-227164767-T-C, REVEL 0.52, CADD 13.20
- P15L (p.Pro15Leu), NCI-TCGA TCGA novel, TOPMed rs1260966222, gnomAD rs1260966222, REVEL 0.23, CADD 0.01, Uncertain significance
- P15R (p.Pro15Arg), rs1260966222, ClinGen CA350846071, ClinVar RCV001307150, ClinVar RCV002476414, REVEL 0.28, CADD 0.00, Uncertain significance, Autosomal dominant Alport syndrome; Autosomal recessive Alport syndrome; Benign
- p.Pro15 Leu18del, rs570469692, gnomAD 2-227164758-TGCTC, CADD 13.50
- P15S (p.Pro15Ser), gnomAD 2-227164769-C-T, REVEL 0.16, CADD 8.51
- P15T (p.Pro15Thr), gnomAD 2-227164769-C-A, REVEL 0.15, CADD 8.62
- P15A (p.Pro15Ala), gnomAD 2-227164769-C-G, REVEL 0.20, CADD 7.32
- P15Q (p.Pro15Gln), gnomAD 2-227164770-C-A, REVEL 0.27, CADD 0.00
- P15P (p.Pro15Pro), rs542100614, gnomAD 2-227164771-G-C, CADD 10.40
- L16F (p.Leu16Phe), gnomAD 2-227164772-C-T, REVEL 0.19, CADD 10.30
- L16I (p.Leu16Ile), gnomAD 2-227164772-C-A, REVEL 0.17, CADD 11.00
- L16P (p.Leu16Pro), gnomAD 2-227164773-T-C, REVEL 0.50, CADD 19.10
- L16H (p.Leu16His), gnomAD 2-227164773-T-A, REVEL 0.37, CADD 20.40
- L16L (p.Leu16Leu), rs1160996300, gnomAD 2-227164774-C-G, CADD 7.47
- L17M (p.Leu17Met), gnomAD rs1392367404, REVEL 0.35, CADD 14.80
- L17Q (p.Leu17Gln), TOPMed rs1286962739
- L17P (p.Leu17Pro), gnomAD 2-227164776-T-C, REVEL 0.53, CADD 19.50
- L17L (p.Leu17Leu), gnomAD 2-227164777-G-T, CADD 8.75
- L18P (p.Leu18Pro), rs767333630, ExAC rs767333630, REVEL 0.52, CADD 23.80, Variant assessed as somatic; moderate impact.
- p.Leu18 Leu21del, rs940074065, gnomAD 2-227164770-CGCTC, CADD 16.10
- L18L (p.Leu18Leu), rs1245481661, gnomAD 2-227164778-C-T, CADD 9.84
- V19M (p.Val19Met), Ensembl rs2065149681, REVEL 0.22, CADD 9.56
- V19L (p.Val19Leu), gnomAD 2-227164781-G-C, REVEL 0.28, CADD 4.31
- V19A (p.Val19Ala), gnomAD 2-227164782-T-C, REVEL 0.17, CADD 15.30
- V19V (p.Val19Val), rs2065149896, gnomAD 2-227164783-G-T, CADD 10.50
- L20I (p.Leu20Ile), gnomAD 2-227164784-C-A, REVEL 0.13, CADD 15.50
- L20F (p.Leu20Phe), gnomAD 2-227164784-C-T, REVEL 0.17, CADD 13.50
- L20P (p.Leu20Pro), gnomAD 2-227164785-T-C, REVEL 0.47, CADD 19.50
- L20H (p.Leu20His), gnomAD 2-227164785-T-A, REVEL 0.36, CADD 22.10
- L20L (p.Leu20Leu), rs772992743, gnomAD 2-227164786-C-T, CADD 7.22
- L21P (p.Leu21Pro), Ensembl rs2065150280, REVEL 0.32, AlphaMissense 0.11, Uncertain significance, Inborn genetic diseases
- L21Q (p.Leu21Gln), rs2065150280, ClinGen CA350846160, ClinVar RCV003541933, AlphaMissense 0.11, MetaLR 0.46, Uncertain significance, not provided
- L21V (p.Leu21Val), gnomAD 2-227164787-C-G, REVEL 0.23, CADD 19.50
- L21M (p.Leu21Met), gnomAD 2-227164787-C-A, REVEL 0.21, CADD 23.20
- L21R (p.Leu21Arg), gnomAD 2-227164788-T-G, REVEL 0.49, CADD 23.20
- L21L (p.Leu21Leu), rs1036829250, gnomAD 2-227164789-G-A, CADD 14.20
- A22E (p.Ala22Glu), TOPMed rs898269106, gnomAD rs898269106, REVEL 0.30, CADD 11.80, Uncertain significance, Hematuria, benign familial, 2; Alport syndrome 3b, autosomal recessive; Autosoma
- A22P (p.Ala22Pro), gnomAD 2-227164790-G-C, REVEL 0.19, CADD 21.30
- A22V (p.Ala22Val), gnomAD 2-227164791-C-T, REVEL 0.20, CADD 12.70
- A22A (p.Ala22Ala), gnomAD 2-227164792-G-T, CADD 10.10
- A23P (p.Ala23Pro), gnomAD 2-227164792-GGCGG, CADD 24.60
- A23S (p.Ala23Ser), gnomAD 2-227164793-G-T, REVEL 0.17, CADD 13.30
- A23T (p.Ala23Thr), gnomAD 2-227164793-G-A, REVEL 0.17, CADD 15.90
- A23V (p.Ala23Val), gnomAD 2-227164794-C-T, REVEL 0.15, CADD 15.50
- A23E (p.Ala23Glu), gnomAD 2-227164794-C-A, REVEL 0.31, CADD 16.20
- A23A (p.Ala23Ala), gnomAD 2-227164795-G-A, CADD 8.88
- A24G (p.Ala24Gly), rs184704920, ClinGen CA2145894, ClinVar RCV000591094, ClinVar RCV000888221, REVEL 0.11, CADD 12.80, Benign/Likely benign, Kidney disorder; not specified; not provided
- A24del (p.Ala24del), rs2065150724, gnomAD 2-227164788-TGGC-, CADD 21.40
- p.Ala24dup, gnomAD 2-227164788-T-TGG, CADD 21.60
- A24S (p.Ala24Ser), gnomAD 2-227164796-G-T, REVEL 0.13, CADD 11.30
- A24T (p.Ala24Thr), gnomAD 2-227164796-G-A, REVEL 0.13, CADD 13.60
- A24V (p.Ala24Val), gnomAD 2-227164797-C-T, REVEL 0.15, CADD 10.90
- A24E (p.Ala24Glu), gnomAD 2-227164797-C-A, REVEL 0.23, CADD 11.20
- A24A (p.Ala24Ala), gnomAD 2-227164798-G-A, CADD 9.43
- P25S (p.Pro25Ser), rs139271412, ClinGen CA2145895, ClinVar RCV000243130, ClinVar RCV000968555, REVEL 0.17, CADD 6.54, Benign/Likely benign, Kidney disorder; not specified; not provided
- P25T (p.Pro25Thr), gnomAD 2-227164799-C-A, REVEL 0.19, CADD 8.53
- P25P (p.Pro25Pro), gnomAD 2-227164801-C-A, CADD 6.48
- A26E (p.Ala26Glu), TOPMed rs1361533883, gnomAD rs1361533883, REVEL 0.12, CADD 9.81
- A26Q (p.Ala26Gln), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- A26T (p.Ala26Thr), gnomAD rs1298369205, REVEL 0.20, CADD 9.35
- A26V (p.Ala26Val), TOPMed rs1361533883, gnomAD rs1361533883, REVEL 0.09, CADD 10.20
- A26P (p.Ala26Pro), gnomAD 2-227164800-CCGCA, CADD 22.20
- A26S (p.Ala26Ser), gnomAD 2-227164802-G-T, REVEL 0.15, CADD 7.48
- A26A (p.Ala26Ala), gnomAD 2-227164804-A-G, CADD 5.20
- A27D (p.Ala27Asp), rs1244132148, ClinGen CA350846267, ClinVar RCV003732896, ClinVar RCV005545085, REVEL 0.16, CADD 7.49, Uncertain significance, Inborn genetic diseases; not provided
- A27T (p.Ala27Thr), TOPMed rs1327569810, gnomAD rs1327569810, REVEL 0.07, CADD 11.70
- A27V (p.Ala27Val), gnomAD 2-227164806-C-T, REVEL 0.17, CADD 8.00
- A27A (p.Ala27Ala), gnomAD 2-227164807-C-A, CADD 5.32
- S28G (p.Ser28Gly), gnomAD rs2065153072, REVEL 0.15, CADD 9.54
- S28R (p.Ser28Arg), Ensembl rs2065153270, REVEL 0.19, CADD 16.90
- S28A (p.Ser28Ala), gnomAD 2-227164805-GC-G, CADD 20.30
- S28N (p.Ser28Asn), gnomAD 2-227164809-G-A, REVEL 0.17, CADD 16.20
- S28I (p.Ser28Ile), gnomAD 2-227164809-G-T, REVEL 0.21, CADD 17.20
- S28S (p.Ser28Ser), gnomAD 2-227164810-C-T, CADD 14.90
- K29M (p.Lys29Met), rs999240932, ClinGen CA66565557, ClinVar RCV001814696, TOPMed rs999240932, REVEL 0.53, CADD 33.00, Uncertain significance, Inborn genetic diseases; not provided
- K29N (p.Lys29Asn), Ensembl rs2065153716, REVEL 0.34, CADD 32.00, Uncertain significance
- K29R (p.Lys29Arg), rs999240932, ClinGen CA350846310, ClinVar RCV002223018, TOPMed rs999240932, REVEL 0.31, CADD 24.30, Uncertain significance, not specified
- K29T (p.Lys29Thr), gnomAD 2-227164812-A-C, REVEL 0.46, CADD 25.80
- K29K (p.Lys29Lys), rs2065153716, gnomAD 2-227164813-G-A, CADD 23.20
- G30D (p.Gly30Asp), Ensembl rs2068790420, REVEL 0.44, CADD 25.40
- G30R (p.Gly30Arg), rs1559854632, ClinGen CA350857960, ClinVar RCV000681943, Ensembl rs1559854632, REVEL 0.53, CADD 25.40, Likely pathogenic, not provided
- G30V (p.Gly30Val), gnomAD 2-227237969-G-T, REVEL 0.61, CADD 25.30
- G30G (p.Gly30Gly), rs988459674, gnomAD 2-227237970-T-C, CADD 11.00
- C31Y (p.Cys31Tyr), Ensembl rs2068790823
- C31R (p.Cys31Arg), gnomAD 2-227237971-T-C, REVEL 0.73, CADD 25.70
- V32A (p.Val32Ala), gnomAD 2-227237975-T-C, REVEL 0.22, CADD 17.00
- C33V (p.Cys33Val), gnomAD 2-227237976-CT-C, CADD 26.90
- C33R (p.Cys33Arg), gnomAD 2-227237977-T-C, REVEL 0.65, CADD 26.20
- C33Y (p.Cys33Tyr), gnomAD 2-227237978-G-A, REVEL 0.65, CADD 26.00
- C33C (p.Cys33Cys), gnomAD 2-227237979-T-C, CADD 6.72
- K34* (p.Lys34Ter), gnomAD rs2068791080, CADD 36.00
- K34R (p.Lys34Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K34L (p.Lys34Leu), rs1385106410, gnomAD 2-227237970-T-TTG, CADD 25.90
- K34E (p.Lys34Glu), gnomAD 2-227237980-A-G, REVEL 0.20, CADD 13.80
- D35E (p.Asp35Glu), TOPMed rs2068791219
- D35H (p.Asp35His), NCI-TCGA Cosmic COSV6741, Variant assessed as somatic; moderate impact.
- D35T (p.Asp35Thr), gnomAD 2-227237979-TA-T, CADD 22.50
- G37D (p.Gly37Asp), NCI-TCGA Cosmic COSV6741, Variant assessed as somatic; moderate impact.
- G37S (p.Gly37Ser), TOPMed rs2068791334
- G37C (p.Gly37Cys), gnomAD 2-227237989-G-T, REVEL 0.53, CADD 24.70
- G37G (p.Gly37Gly), rs1246881535, gnomAD 2-227237991-C-T, CADD 14.30
- Q38E (p.Gln38Glu), rs201607115, ClinGen CA2145906, ClinVar RCV000380561, ClinVar RCV000907824, REVEL 0.21, CADD 15.10, Conflicting interpretations, Inborn genetic diseases; not provided; Alport syndrome
- Q38H (p.Gln38His), TOPMed rs772640950, gnomAD rs772640950, REVEL 0.27, CADD 22.50
- Q38R (p.Gln38Arg), ExAC rs774982255, TOPMed rs774982255, gnomAD rs774982255, REVEL 0.27, CADD 12.30, Uncertain significance, Inborn genetic diseases
- Q38Q (p.Gln38Gln), gnomAD 2-227237994-G-A, CADD 7.69
- C39S (p.Cys39Ser), TOPMed rs1463080946, gnomAD rs1463080946, REVEL 0.69, CADD 25.00
- C39Y (p.Cys39Tyr), TOPMed rs2068792091, REVEL 0.64, CADD 25.50
- C39F (p.Cys39Phe), gnomAD 2-227237996-G-T, REVEL 0.65, CADD 25.50
- C39* (p.Cys39Ter), gnomAD 2-227237997-C-A, CADD 36.00
- F40Y (p.Phe40Tyr), gnomAD 2-227237999-T-A, REVEL 0.23, CADD 19.70
- F40F (p.Phe40Phe), gnomAD 2-227238000-C-T, CADD 11.60
- F40L (p.Phe40Leu), gnomAD 2-227238000-C-A, REVEL 0.19, CADD 17.40
- C41R (p.Cys41Arg), TOPMed rs2068792259
- C41Y (p.Cys41Tyr), gnomAD rs921708396, REVEL 0.72, CADD 25.10
- C41C (p.Cys41Cys), rs1261122382, gnomAD 2-227238003-T-C, CADD 5.17
- C41* (p.Cys41Ter), gnomAD 2-227238003-T-A, CADD 35.00
- D42G (p.Asp42Gly), ExAC rs747725232, gnomAD rs747725232, REVEL 0.28, CADD 10.50
- D42Y (p.Asp42Tyr), gnomAD 2-227238004-G-T, REVEL 0.39, CADD 13.90
- D42N (p.Asp42Asn), gnomAD 2-227238004-G-A, REVEL 0.29, CADD 12.40
- D42E (p.Asp42Glu), gnomAD 2-227238006-C-A, REVEL 0.30, CADD 0.00
- D42D (p.Asp42Asp), rs369251968, gnomAD 2-227238006-C-T, CADD 0.03
- G43A (p.Gly43Ala), ExAC rs776294835, TOPMed rs776294835, gnomAD rs776294835, REVEL 0.45, CADD 20.20
- G43E (p.Gly43Glu), ExAC rs776294835, TOPMed rs776294835, gnomAD rs776294835, REVEL 0.51, CADD 21.80
- G43R (p.Gly43Arg), rs2469447948, ClinGen CA2825001094, ClinVar RCV004526563, REVEL 0.42, CADD 22.40, Likely benign, not specified; not provided; Alport syndrome
- G43W (p.Gly43Trp), 1000Genomes rs13424243, ESP rs13424243, ExAC rs13424243, TOPMed rs13424243, REVEL 0.46, CADD 22.60, Uncertain significance, Autosomal dominant Alport syndrome
- G43V (p.Gly43Val), gnomAD 2-227238008-G-T, REVEL 0.58, CADD 21.60
Public COL4A3 analysis runs
- COL4A3 analysis run — COL4A3 (2,407 variants) — completed 2026-08-19